Journal of Neuro-Oncology

, Volume 76, Issue 2, pp 99–104 | Cite as

Targeted Tumor Cell Death Induced by Autologous Tumor-Specific T Lymphocyte Recognition of Wild-Type p53-Derived Peptides

  • Hideo Tsurushima
  • Yoshihiko Yoshii
  • Kam W Leong
  • Tadao Ohno
Laboratory Investigation


Autologous tumor-specific T lymphocyte (ATTL) lines were derived from the peripheral blood mononuclear cells (PBMC) of a healthy volunteer with human leukocyte antigen (HLA) -A*0201. These lines were achieved using interleukins -1β, -2, -4, and -6 and the p53-based peptide from the 264–272 sequence of the wild-type p53 protein with a strong affinity against HLA-A*0201.

;The frequencies of CD3+, CD4+, and CD8+ lymphocytes were 94–96%, 30–34%, and 69–74%, respectively. ATTLs killed most of the T2 cells pulsed with p53-derived peptide, but not against the T2 cells non-pulsed or pulsed with an irrelevant peptide. ATTLs also killed TKB-14 cells, which have been derived from human glioblastoma multiforme, and exhibited HLA-A*0201 molecule and immunohistochemical accumulation of p53 protein. These cytotoxic activities were inhibited by anti-CD3, anti-CD8, and anti-class I antibodies.

These findings suggested that these ATTL lines might include CTL populations, which could recognize p53-derived peptide on HLA-A*0201 and the p53-based peptide may play as an antigen on HLA-A*0201. When tumor antigens would be more analyzed in the future, ATTL could be induced without the primary-cultured cells from tumor tissue and could be applied for cancer therapy.


antigen presentation cytotoxic T lymphocyte glioblastoma multiforme p53-immunopeptide 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Holladay, FP, Heitz, T, Wood, GW 1992Antitumor activity against established intracerebral glioma exhibited by cytotoxic T lymphocytes, but not lymphokine-activated killer cellsJ Neurosurg77757762PubMedGoogle Scholar
  2. 2.
    Ikarashi, H, Fujita, K, Takakuwa, K, Kodama, S, Tokunaga, A, Takahashi, T, Tanaka, K 1994Immunomodulation in patients with epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytesCancer Res54190196PubMedGoogle Scholar
  3. 3.
    Kawakami, Y, Eliyahu, S, Delgado, CH, Robbins, PF, Sakaguchi, K, Appella, E, Yannelli, JR, Adema, GJ, Miki, T, Rosenberg, SA 1994Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejectionProc Natl Acad Sci USA9164586462PubMedGoogle Scholar
  4. 4.
    Rosenberg, SA, Lotze, MT, Muul, LM, Chang, AE, Avis, FP, Leitman, S, Linehan, WM, Robertson, CN, Lee, RE, Rubin, JT, Seipp, CA, Simpson, CG, White, DE 1987A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 aloneNew Engl J Med316889897PubMedGoogle Scholar
  5. 5.
    Rosenberg, SA, Aebersold, P, Cornetta, K, Kasid, A, Morgan, RA, Moen, R, Karson, EM, Lotze, MT, Yang, JC, Topalian, SL, Merino, MJ, Culver, K, Miller, AD, Blaese, RM, Anderson, WF 1990Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumor infiltrating lymphocytes modified by retroviral gene transductionNew Engl J Med323570578PubMedGoogle Scholar
  6. 6.
    Slingluff, CL, Cox, AL, Stover, JM, Moore, MM, Hunt, DF, Engelhard, VM 1994Cytotoxic T-lymphocyte response to autologous human squamous cell cancer of the lung: epitope reconstitution with peptides extracted from HLA-Aw68Cancer Res5427312737PubMedGoogle Scholar
  7. 7.
    Tjoa, BA, Kranz, DM 1994Generation of cytotoxic T-lymphocytes to a self-peptide/class I complex: a model for peptide-mediated tumor rejectionCancer Res54204208PubMedGoogle Scholar
  8. 8.
    Tsurushima, H, Liu, SQ, Tuboi, K, Matsumura, A, Yoshii, Y, Nose, T, Saijo, K, Ohno, T 1999Reduction of end-stage malignant gliomas by injection with autologous cytotoxic T lymphocytesJpn J Cancer Res90536545PubMedGoogle Scholar
  9. 9.
    Tsuboi, K, Saijo, K, Ishikawa, E, Tsurushima, H, Takano, S, Morishita, Y, Ohno, T 2003Efffects of local injection of ex vivo expanded autologous tumor-specific T lymphocytes in cases with recurrent malignant gliomasClin Cancer Res1532943302Google Scholar
  10. 10.
    Crowley, NJ, Darrow, TL, Quinnallen, MA, Seigler, HF 1991MHC-restricted recognition of autologous melanoma by tumor-specific cytotoxic T cells – evidence for restriction by a diminant HLA-A alleleJ Immunol14616921699PubMedGoogle Scholar
  11. 11.
    Wolfel, T, Herr, W, Coulie, P, Schmitt, U, Zumbuschenfelde, KHM, Knuth, A 1993Lysis of human pancreatic adenocarcinoma cells by autologous HLA-class I-restricted cytotoxic T-lymphocyte (CTL) clonesInt J Cancer54636644PubMedGoogle Scholar
  12. 12.
    Tsurushima, H, Liu, SQ, Tsuboi, K, Yoshii, Y, Nose, T, Ohno, T 1996Induction of human cytotoxic T lymphocytes against minced tissues of glioblastoma multiformeJ Neurosurg84258263PubMedGoogle Scholar
  13. 13.
    Horiuchi, K, Tsurushima, H, Kim, BS, Liu, SQ, Saijo, K, Saijo, Y, Nukiwa, T, Nomura, N, Matsumura, M, Ohno, T 1998Expansion of human autologous cytotoxic T lymphocytes on fixed target tumor cellsCytotechnology26119124CrossRefGoogle Scholar
  14. 14.
    Liu, SQ, Saijo, K, Todoroki, T, Ohno, T 1995Induction of human autologous cytotoxic T lymphocytes on formalin-fixed and paraffin-embedded tumor sectionsNat Med1267271PubMedGoogle Scholar
  15. 15.
    Liu, SQ, Shiraiwa, H, Kawai, K, Hayashi, H, Akaza, H, Kim, BS, Oki, A, Nishida, M, Kubo, T, Hashizaki, K, Saijo, K, Ohno, T 1996Tumor-specific autologous cytotoxic T lymphocytes from tissue sectionsNat Med21283PubMedGoogle Scholar
  16. 16.
    Gnjatic, S, Depaillerets, BB, Guillet, JG, Choppin, J 1995Mapping and ranking of potential cytotoxic T epitopes in the p53 protein: effect of mutations and polymorphism on peptide binding to purified and refolded HLA moleculesEur J Immunol2516381642PubMedGoogle Scholar
  17. 17.
    Houbiers, JGA, Nijman, HW, Vanderburg, SH, Drijfhout, JW, Kenemans, P, Vandevelde, CJH, Brand, A, Momburg, F, Kast, WM, Melief, CJM 1993In vitro induction of human cytotoxic T lymphocytes responses against peptide of mutant and wild-type p53Eur J Immunol2320722077PubMedGoogle Scholar
  18. 18.
    Stuber, G, Leder, GH, Storkus, WJ, Lotze, MT, Modrow, S, Szekely, L, Wolf, H, Klein, E, Karre, K, Klein, G 1994Identification of wild-type and mutant p53 peptide binding to HLA-A2 assessed by a novel major histocompatibility complex class I peptide binding assayEur J Immunol24765768PubMedGoogle Scholar
  19. 19.
    Ropke, M, Hald, J, Guldberg, P, Zeuthen, J, Norgaard, L, Fugger, L, Svejgaard, A, Vanderburg, S, Nijman, HW, Melief, CJ, Claesson, MH 1996Spontaneous human squamous cell carcinoma are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptideProc Natl Acad Sci USA9314041407CrossRefGoogle Scholar
  20. 20.
    Gnjatic, S, Cai, Z, Viguier, M, Chouaib, S, Guillet, JG, Choppin, J 1998Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomasJ Immunol160328333PubMedGoogle Scholar
  21. 21.
    Crawford, LV, Pim, DC, Bulbrook, RD 1982Detection of antibodies against the cellular protein p53 in sera from patients with breast cancerInt J Cancer30403408PubMedGoogle Scholar
  22. 22.
    Soussi, T 1996The humoral response to the tumor-suppressor gene-product p53 in human cancer: implications for diagnosis and therapyImmunol Today17354356CrossRefPubMedGoogle Scholar
  23. 23.
    Soong, R, Robbins, PD, Dix, BR, Grieu, F, Lim, B, Knowles, S, Williams, KE, Turbett, GR, House, AK, Iacopetta, BJ 1996Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomasHum Pathol2710501055CrossRefPubMedGoogle Scholar
  24. 24.
    Watanabe, K, Sato, K, Biernat, W, Tachibana, O, vonAmmon, K, Ogata, N, Yonekawa, Y, Kleihues, P, Ohgaki, H 1997Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsiesClin Cancer Res3523530PubMedGoogle Scholar
  25. 25.
    Ropke, M, Regner, M, Claesson, MH 1995T cell-mediated cytotoxity against p53-protein derived peptides in bulk and limiting dilution cultures of healthy donorsScand J Immunol4298103PubMedGoogle Scholar
  26. 26.
    Nijman, HW, Houbiers, JGA, Vanderburg, SH, Vierboom, MPM, Kenemans, P, Kast, WM, Melief, CJM 1993Characterization of cytotoxic T lymphocyte epitopes of a self-protein, p53, and a non-self-protein, influenza matrix: relationship between major histocompatibility complex peptide binding affinity and immune responsiveness to peptidesJ Immunother14121126PubMedGoogle Scholar
  27. 27.
    Chikamatsu, K, Nakano, K, Storkus, WJ, Appella, E, Lotze, MT, Whiteside, TL, DeLeo, AB 1999Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cellsClin Cancer Res512811288PubMedGoogle Scholar
  28. 28.
    Oren, M, Maltzman, W, Levine, AJ 1981Posttranslational regulation of the 54K cellular tumor antigen in normal and transformed cellsMol Cell Biol1101110PubMedGoogle Scholar
  29. 29.
    Jial, LG, Osada, M, Ishioka, C, Gamo, M, Iwaki, S, Suzuki, T, Shimodaira, H, Niitani, T, Kudo, T, Akiyama, M, Kimura, N, Matsuo, M, Mizusawa, H, Tanaka, N, Koyama, H, Namba, M, Kanamaru, R, Kuroki, T 1997Study of p53 status of cultured cell lines maintained mainly in the JCRB cell bankMol Carcinogen19243253Google Scholar

Copyright information

© Springer 2005

Authors and Affiliations

  • Hideo Tsurushima
    • 1
    • 2
    • 3
  • Yoshihiko Yoshii
    • 1
  • Kam W Leong
    • 3
  • Tadao Ohno
    • 2
  1. 1.Faculty of Medicine, Department of Neuro SurgeryUniversity of the RyukyusOkinawaJapan
  2. 2.RIKEN Cell Bank, RIKENThe Institute of Physical and Chemical ResearchTsukuba Science CityJapan
  3. 3.Department of Biomedical Engineering, School of MedicineJohns Hopkins UniversityUSA
  4. 4.Nanotechnology Research Institute (NRI)National Institute of Advanced Industrial Science and Technology (AIST)IbarakiJapan

Personalised recommendations